Skip to Main Content

Cyclerion Therapeutics, Inc. Common Stock

CYCN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
CYCN Income Statement
CYCN Balance Sheet
CYCN Cash Flow

Recent trades of CYCN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CYCN Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CYCN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CYCN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by CYCN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Processes and intermediates for the preparation of soluble guanylate cyclase stimulators Jul. 09, 2024
  • Patent Title: Processes for preparation of soluble guanylate cyclase stimulators Dec. 05, 2023
  • Patent Title: Process for preparation of soluble guanylate cyclase stimulators Oct. 03, 2023
  • Patent Title: Sgc stimulators Aug. 22, 2023
  • Patent Title: Processes and intermediates for the preparation of soluble guanylate cyclase stimulators Jul. 25, 2023
  • Patent Title: Treatment of cns diseases with sgc stimulators Jul. 04, 2023
  • Patent Title: Solid forms of an sgc stimulator Feb. 07, 2023
  • Patent Title: Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1h-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sgc stimulators Oct. 11, 2022
  • Patent Title: Process for preparing soluble guanylate cyclase stimulators Oct. 11, 2022
  • Patent Title: Treatment of metabolic syndrome with an sgc stimulator Jul. 19, 2022
  • Patent Title: Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash) Jun. 14, 2022
  • Patent Title: Processes for preparation of soluble guanylate cyclase stimulators May. 03, 2022
  • Patent Title: Processes and intermediates for the preparation of soluble guanylate cyclase stimulators Mar. 15, 2022
  • Patent Title: Sgc stimulators Dec. 28, 2021
  • Patent Title: Sgc stimulators Nov. 23, 2021
  • Patent Title: Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulators Feb. 23, 2021
  • Patent Title: Solid forms of an sgc stimulator Jan. 12, 2021
  • Patent Title: Sgc stimulators Dec. 08, 2020
  • Patent Title: Sgc stimulators Nov. 24, 2020
  • Patent Title: Sgc stimulators May. 05, 2020
  • Patent Title: Sgc stimulators Dec. 31, 2019
  • Patent Title: Sgc stimulators Nov. 12, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CYCN in WallStreetBets Daily Discussion

CYCN News

Recent insights relating to CYCN

CNBC Recommendations

Recent picks made for CYCN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CYCN

CYCN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CYCN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top